Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
about
Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD)Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesThree Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple Organ Failure Outcome.Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports.Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Update on the long-term complications of renal transplantation.Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.Multiple infections and cancer: implications in epidemiology.Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management.Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis.T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach.Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell TransplantThe efficacy of EBER in situ hybridization (ISH) stain in PTLD (malignant diffuse large B-cell lymphoma) about 4 years after ABO-incompatible kidney transplantation: a case reportAsymptomatic post-transplant lymphoproliferative disorder diagnosed at one year protocol renal allograft biopsy.Post-transplant lymphoproliferative disorder after pancreas transplantation: a United Network for Organ Sharing database analysis.Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients.Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors.Primary cutaneous marginal zone lymphoma with sequential development of nodal marginal zone lymphoma in a patient with selective immunoglobulin A deficiency.Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts: A case report and literature review.BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre StudyPost-transplant malignancy: a burdensome complication in renal allograft recipients in KoreaPrimary Intrarenal Posttransplant Lymphoproliferative Disorder Detected by Surveillance Protocol BiopsyPosttransplant Lymphoproliferative Disorder after Cardiac Transplantation in Children: Life Threatening Complications Associated with Chemotherapy Combined with Rituximab
P2860
Q26749007-592790B5-F226-4CFD-AC8C-011904AA4293Q26852437-D520DF7A-3A3D-4DFD-B3BD-1F9A60B5A177Q33441000-9E613921-3AA1-4D58-802F-A16FA651492EQ34388117-31B18641-F875-42E4-8EA2-3AB6E4C7B7AEQ36940100-F4D5484C-F700-4262-A06D-C8BB6DDA8133Q37145738-01A59A10-2C60-4C06-A8A2-B8BA2EB4E73AQ37355856-625E1CF2-6F01-4D11-8751-B2C81C9DE808Q37975458-CCBD52C3-1F65-4AD3-BE8B-6E88F34AF586Q38032320-6917C352-C6D8-475B-8526-8C5AD8DC13E3Q38104335-BFAC5985-CDFE-4A4F-B5D1-ABB64E4884F7Q38112050-C662B1E9-D600-411F-BB9D-B53459110574Q38126931-BEA913F5-A865-4D0E-8ED5-880D7E2E0542Q38669053-8277A602-2F1B-43D6-90AC-B32FE30D6CA2Q38680172-583B08C5-DF48-4FBF-8662-F8FF3D10DD4CQ38897604-FA1E6208-BDDA-41AC-ADDE-3DCDA477C627Q39022877-E7B6BEAA-5ED3-4B44-981B-96A4C4E039E8Q40389653-05DCC412-720B-4857-AFFD-27A90ACC0C6DQ40492215-EA5C8AFF-A606-49EC-A354-F92E9E2F6E2EQ40656850-5D1D43CC-1974-4509-803C-D8677376BBECQ40723071-646D2251-6FCB-4134-82A1-59E452B10F29Q42025417-018F8EF7-9616-4AAA-A452-1E78FC7F7C98Q42182928-5608F5A2-8CC3-422B-BC59-4AC3B9ED03E0Q42217743-FA2891DF-4A58-4DC3-8F8D-F6BEC3AD9039Q42263131-F3331A54-702A-49BA-9C29-49CBBAA11918Q44293440-14AE137E-D521-49C6-828C-FE4893697D20Q50092833-C8C26F6C-3820-42C5-AB96-7FC765946114Q54538547-3BF38554-885F-4C81-AABC-943AEFE887ACQ55080580-A0BD8905-F4E1-46D1-885F-7E255D6BCA79Q56957209-FDACE040-FD0A-4C07-A67B-8701B2A3ABE6Q57223044-9EAEBE3D-F456-4675-98CA-33661B33C5B4Q58004260-613C9CCB-B4B5-43D3-87BC-60F614AA9276Q58998353-88D73B88-A627-4212-B272-B6E00B2D9FA5
P2860
Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lymphoproliferative disorders ...... tection and treatment options.
@en
Lymphoproliferative disorders ...... tection and treatment options.
@nl
type
label
Lymphoproliferative disorders ...... tection and treatment options.
@en
Lymphoproliferative disorders ...... tection and treatment options.
@nl
prefLabel
Lymphoproliferative disorders ...... tection and treatment options.
@en
Lymphoproliferative disorders ...... tection and treatment options.
@nl
P2093
P2860
P1476
Lymphoproliferative disorders ...... tection and treatment options.
@en
P2093
Anna Sebestyén
Gyula Végso
Melinda Hajdu
P2860
P2888
P304
P356
10.1007/S12253-010-9329-8
P577
2010-12-31T00:00:00Z